Affimed N.V.

It looks like the end of the road for oncology specialist Affimed, the latest sorry tale of an early-stage biotech that failed to raise the cash for a promising pipeline. The German group filed for in

Germany’s 4SC faces an uncertain future after regulators in Europe dashed any hopes that Kinselby would become the first approved maintenance therapy for cutaneous T-cell lymphoma (CTCL). The Planegg-

In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Under the lead

Artiva Biotherapeutics, Inc. ’s initial public offering late on 18 July reflected the mixed bag that the IPO market has become. To get the offering through the IPO window at a time when first-time off